EFFICACY AND SAFETY OF ORAL OCTREOLIN™ IN PATIENTS WITH ACROMEGALY WHO ARE CURRENTLY RECEIVING PARENTERAL SOMATOSTATIN ANALOGS

Chiasma, Inc.0 个研究点目标入组 150 人开始时间: 2012年9月24日最近更新: 2014年10月27日

适应症

试验速览

暂无简介。

•1.Adult subjects, aged 18 to 75 years old, inclusive, at screening visits
•2.Subjects with acromegaly defined as documented evidence of GH-secreting pituitary tumor that is abnormally responsive to glucose who are currently receiving somatostatin analog.
•3.Subjects able and willing to comply with the requirements of the protocol
•4.Subjects able to swallow capsules
•5.Subjects able to understand and sign written informed consent to participate in the study
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 132
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 18

•1.Symptomatic cholelithiasis
•2.Received pituitary radiotherapy within ten years prior to screening
•3.Undergone pituitary surgery within the prior 6 months
•4.Clinically significant GI, renal or hepatic disease. 5.Known allergy or hypersensitivity to any of the test compounds or materials
•6.Life expectancy of less than 2 years
•7.Uncontrolled diabetes
•8.Defects in visual fields due to optic chiasmal compression
•9.Female patients who are pregnant or lactating
•10.Female patients who are of childbearing potential 11.History of immunocompromise, including a positive HIV test result (ELISA and Western blot)
•12.History of alcohol or drug abuse
•13.Intake of an investigational drug within 30 days before patient inclusion in this study

发起方